Publications
2012
Biot C, Rentsch CA, Gsponer JR, Birkhäuser FD, Jusforgues-Saklani H, Lemaître F, Auriau C, Bachmann A, Bousso P, Demangel**C, Peduto L, Thalmann GN, Albert ML. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. *Sci Transl Med.*(2012) 6;4(137):137ra72.
Houben D, Demangel**C, van Ingen J, Perez J, Baldeón L, Abdallah AM, Caleechurn L, Bottai D, van Zon M, de Punder K, van der Laan T, Kant A, Bossers-de Vries R, Willemsen P, Bitter W, van Soolingen D, Brosch R, van der Wel N, Peters PJ. ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria. *Cell Microbiol*. (2012) 14(8):1287-98.
2011
Chany AC, Casarotto V, Schmitt M, Tarnus C, Guenin-Macé L, Demangel C, Mirguet O, Eustache J, Blanchard N. A diverted total synthesis of mycolactone analogues: an insight into Buruli ulcer toxins. Chemistry (2011) 16;17(51):14413-9.
Sarfo FS, Le Chevalier F, Aka N, Phillips RO, Amoako Y, Boneca IG, Lenormand P, Dosso M, Wansbrough-Jones M, Veyron-Churlet R, Guenin-Macé L, Demangel C. Mycolactone diffuses into the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring.PLoS Negl Trop Dis (2011) 5(7):e1237.
Guenin-Macé L, Carrette F, Asperti-Boursin F, Le Bon A, Caleechurn L, Di Bartolo V, Fontanet A, Bismuth G, Demangel C. Mycolactone impairs T cell homing by suppressing microRNA control of L-selectin expression. Proc Natl Acad Sci U S A (2011) 108(31):12833-8.
2010
Mostowy S, Bonazzi M, Hamon MA, Tham TN, Mallet A, Lelek M, Gouin E, Demangel C, Brosch R, Zimmer C, Sartori A, Kinoshita M, Lecuit M, Cossart P. Entrapment of intracytosolic bacteria by septin cage-like structures. Cell Host Microbe (2010) 18;8(5):433-44.
Tabouret G, Astarie-Dequeker C, Demangel C, Malaga W, Constant P, Ray A, Honoré N, Bello NF, Perez E, Daffé M, Guilhot C. Mycobacterium leprae phenolglycolipid-1 expressed by engineered M. bovis BCG modulates early interaction with human phagocytes.PLoS Pathog (2010) 21;6(10):e1001159.
Boulkroun S, Guenin-Macé L, Thoulouze MI, Monot M, Merckx A, Langsley G, Bismuth G, Di Bartolo V, Demangel C. Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events.J Immunol (2010) 184(3):1436-44.
2009
Phillips R, Sarfo FS, Guenin-Macé L, Decalf J, Wansbrough-Jones M, Albert ML, Demangel C. Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease.J Infect Dis (2009)200(11):1675-84.
Guenin-Macé L, Siméone R, Demangel C. Lipids of pathogenic Mycobacteria: contributions to virulence and host immune suppression. Transbound Emerg Dis (2009) 56(6-7):255-68. Epub 2009 May 26. Review.
Huygen K, Adjei O, Affolabi D, Bretzel G, Demangel C, Fleischer B, Johnson RC, Pedrosa J, Phanzu DM, Phillips RO, Pluschke G, Siegmund V, Singh M, van der Werf TS, Wansbrough-Jones M, Portaels F. Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol (2009)198(2):69-77. Epub 2009 Feb 7. Review.
Demangel C, Stinear TP, Cole ST. Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol (2009) 7(1):50-60. Review.
2008
Hong H, Coutanceau E, Leclerc M, Caleechurn L, Leadlay PF, Demangel C. Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs.PLoS Negl Trop Dis (2008) 22(10):e325.
Hong H, Demangel C, Pidot SJ, Leadlay PF, Stinear T. Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep (2008) 25(3):447-54. Review.
2007
Hong H, Stinear T, Porter J, Demangel C, Leadlay PF. A novel mycolactone toxin obtained by biosynthetic engineering. Chembiochem (2007) 23;8(17):2043-7. No abstract available.
Coutanceau E, Decalf J, Martino A, Babon A, Winter N, Cole ST, Albert ML, Demangel C. Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med (2007) 11;204(6):1395-403.